1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Roche’s Xofluza Can Reduce Flu Transmission, Giving It Potential Market Boost

 
• By Alaric DeArment

The company said the CENTERSTONE study marked the first time a global Phase III trial showed reduced transmission of influenza.

• Source: Shutterstock

Roche Holding AG’s Xofluza (baloxavir marboxil) stands to strengthen its position in the influenza treatment market with new data showing it can reduce transmission of the virus among people living in close quarters, a particularly useful claim given growing concerns about a potential influenza pandemic.

The Swiss drug maker and its Genentech subsidiary announced topline results 19 September from the Phase III CENTERSTONE study showing a reduction in the transmission of influenza viruses for Xofluza, on which is partnered with Shionogi & Co. Ltd.. The trial met the primary endpoint of showing that a single dose of the drug taken orally significantly reduced the likelihood of others in participants’ households contracting the virus

Key Takeaways

  • Phase III topline results showed Roche/Shionogi’s Xofluza can reduce transmission of influenza among people living in close quarters.

  • This is the first evidence of transmission prevention for a flu antiviral

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Pipeline Watch: Six Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Viatris Will File ‘Fast-Acting’ Meloxicam For FDA Approval This Year

 
• By Joseph Haas

Seven years after acquiring it, Viatris will seek approval of a meloxicam formulation for acute pain backed by data from two Phase III studies in post-surgical pain settings.

CRISPR Therapeutics Unveils Promising Early In Vivo Cholesterol-Lowering Results

 
• By Andrew McConaghie

The Phase I results are the best to date among ANGPTL3-targeting candidates in the pipeline, but analysts will wait for further updates before predicting a likely winner.

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

More from R&D

Sanofi R&D Head’s Words Of Wisdom For Biotechs

 
• By Kevin Grogan

Houman Ashrafian tells delegates at Swiss Biotech Day that ‘literally only two things matter in our industry – target credentialing and differentiated pharmacology. The rest is execution.’

Marea Eyes Cardioprotective Benefit With ANGPTL4 Inhibition

 
• By Joseph Haas

Phase IIa data for ANGPTL4-targeted antibody shows reduced triglycerides and remnant cholesterol, which Marea asserts indicates potential to protect against cardiovascular outcomes.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.